VEGFR2 Antibodies

Santa Cruz Biotechnology features a diverse variety of VEGFR2 monoclonal antibodies for research in vascular biology and angiogenesis. VEGFR2 Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) mediates the effects of vascular endothelial growth factor (VEGF), which is essential for blood vessel formation and maintenance. VEGFR2 activation drives endothelial cell proliferation, migration, and survival, making it a significant target in cancer research and therapeutic development. Understanding VEGFR2 function is crucial for uncovering mechanisms of tumor growth and metastasis, as well as developing anti-angiogenic therapies. Researchers can explore VEGFR2's role in various physiological and pathological conditions using specific detection methods. VEGFR2 investigation continues to reveal new insights into vascular development and disease progression. Studying VEGFR2 signaling pathways helps identify potential therapeutic targets for treating vascular disorders. Santa Cruz Biotechnology monoclonal antibodies for VEGFR2 support researchers worldwide in advancing our understanding of vascular biology and developing new therapeutic strategies.